Prof.
Dingwei Ye
Fudan
University Cancer Hospital, China
Email:
dwyeli@yahoo.com.cn, Dwyeli@163.com
Qualifications
1993
M.Sc., Second Military Medical University, China
1992
B.Sc., Shanghai Institute of Oncology, China
Publications (Selected)
-
Chi, K. N., McKay, R. R., Sandhu, S., Arranz, J. A., Barthélémy, P., Hadaschik, B., ... & Rathkopf, D. E. (2025). rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator’s choice in patients with mCRPC. Future Oncology, 1-7.
-
Lu, X., Ye, D., Hu, H., Lei, M., Xue, Z., Kang, N., ... & Wei, X. (2025). A first-in-human trial of intravesical BH011, a novel docetaxel formulation, in patients with high risk non-muscle invasive bladder cancer (HR-NMIBC) after BCG failure: Results from a phase 1 study.
-
Shen, Y., Lu, X., Ma, X., Liu, W., & Ye, D. (2025). Updated efficacy and safety results from ReBirth, a phase II study of risk-based bladder-sparing therapy for MIBC.
-
Zhang, H., & Ye, D. (2024). Anlotinib plus everolimus as first-line treatment for advanced non–clear cell renal cell carcinoma: A single-center, single-arm, phase II trial.
-
Wan, F., Liu, C., Wang, K. Y., Zhai, B., Zou, Y., Yu, H., ... & Ye, D. (2025). First-in-human study of 177Lu-JH020002 in patients with metastatic castration-resistant prostate cancer.
-
Ye, D., Lu, X., Hu, H., Lei, M., He, Z., Yang, K., ... & Wei, X. (2025). Results of BH011 after intravesical administration in patients with CIS and/or papillary non-muscle invasive bladder cancer (NMIBC) after BCG failure: Interim results from a phase I/II clinical trial.
-
Van Der Heijden, M. S., Galsky, M. D., Powles, T., Necchi, A., Ye, D., Zhang, P., ... & Sonpavde, G. P. (2025). Nivolumab plus ipilimumab (NIVO+ IPI) vs gemcitabine-carboplatin (gem-carbo) chemotherapy for previously untreated unresectable or metastatic urothelial carcinoma (mUC): Final results for cisplatin-ineligible patients from the CheckMate 901 trial.
-
Parsonson, A. O., Gandhi, C., Henick, B. S., Schmidt, A. L., Ye, D., Amin, H., ... & Stein, M. N. (2025). DB-1311/BNT324 (a novel B7H3 ADC) in patients with heavily pretreated castrate-resistant prostate cancer (CRPC).
-
Chi, K. N., McKay, R. R., Sandhu, S., Arranz Arija, J. A., Barthelemy, P., Hadaschik, B. A., ... & Rathkopf, D. (2025). A phase 3 trial of the androgen receptor ligand-directed degrader, BMS-986365, versus investigator’s choice in patients with metastatic castration-resistant prostate cancer (CA071-1000-rechARge).
-
Bian, X., Zeng, H., Guo, H., Xing, N., Yang, Y., Xue, B., ... & Ye, D. (2025). Final overall survival (OS) with talazoparib (TALA)+ enzalutamide (ENZA) as an initial treatment in unselected patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the China cohort of the phase 3 TALAPRO-2 trial.
Profile Details
http://www.fucancerinstitute.org/eng/team.asp?BigClassID=2&id=26
https://loop.frontiersin.org/people/736364/overview
https://www.researchgate.net/scientific-contributions/Dingwei-Ye-11626731